Nithya Srinivas
Overview
Explore the profile of Nithya Srinivas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zeidan A, Cook R, Bordoni R, Berenson J, Edenfield W, Mohan S, et al.
Clin Lymphoma Myeloma Leuk
. 2022 Mar;
22(7):523-534.
PMID: 35260349
Background: The Janus kinase (JAK)/signal transducers and activators of transcription pathway has been implicated in the pathogenesis and progression of various hematologic malignancies. JAK1-regulated cytokines stimulate proliferation and growth of...
2.
Oni-Orisan A, Srinivas N, Mehta K, Das J, Nguyen T, Tison G, et al.
Clin Transl Sci
. 2021 Jan;
14(3):784-790.
PMID: 33421282
Although traditional approaches to biomarker discovery have elucidated key molecular markers that have improved drug selection (precision medicine), the discovery of biomarkers that inform optimal dose selection (precision dosing) continues...
3.
Schroeder M, Khoury H, Jagasia M, Ali H, Schiller G, Staser K, et al.
Blood Adv
. 2020 Apr;
4(8):1656-1669.
PMID: 32324888
Acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic cell transplantation (HCT) is a primary cause of nonrelapse mortality and a major barrier to successful transplant outcomes. Itacitinib is a Janus kinase...
4.
Srinivas N, Barbour A, Epstein N, Zhou G, Petusky S, Xun Z, et al.
J Clin Pharmacol
. 2020 Mar;
60(8):1022-1029.
PMID: 32149388
Itacitinib is a novel, selective, Janus kinase 1 inhibitor in development for treatment of graft-versus-host disease. The objective of this study was to assess pharmacokinetics and safety of 300-mg itacitinib...
5.
Srinivas N, Cottrell M, Maffuid K, Prince H, Nelson J, White N, et al.
Antimicrob Agents Chemother
. 2019 Nov;
64(2).
PMID: 31740561
Maraviroc-based regimens have been explored as preexposure prophylaxis (PrEP) against human immunodeficiency virus (HIV). In this study, we utilized mucosal tissue drug exposure data, combined with target concentrations generated ,...
6.
Devanathan A, Pirone J, Akkina R, Remling-Mulder L, Luciw P, Adamson L, et al.
Antimicrob Agents Chemother
. 2019 Oct;
64(1).
PMID: 31611355
For HIV cure strategies like "kick and kill" to succeed, antiretroviral (ARV) drugs must reach effective concentrations in putative viral reservoirs. We characterize penetration of six ARVs in three preclinical...
7.
Srinivas N, Joseph S, Robertson K, Kincer L, Menezes P, Adamson L, et al.
Clin Transl Sci
. 2019 Jan;
12(3):302-311.
PMID: 30675981
Sparse data exist on the penetration of antiretrovirals into brain tissue. In this work, we present a framework to use efavirenz (EFV) pharmacokinetic (PK) data in plasma, cerebrospinal fluid (CSF),...
8.
Srinivas N, Rosen E, Gilliland Jr W, Kovarova M, Remling-Mulder L, De la Cruz G, et al.
Xenobiotica
. 2018 Oct;
49(10):1192-1201.
PMID: 30346892
1. Antiretroviral concentrations in cerebrospinal fluid (CSF) are used as surrogate for brain tissue, although sparse data support this. We quantified antiretrovirals in brain tissue across preclinical models, compared them...
9.
Srinivas N, Maffuid K, Kashuba A
Clin Pharmacokinet
. 2018 Feb;
57(9):1059-1074.
PMID: 29464550
Despite contributing significantly to the burden of global disease, the translation of new treatment strategies for diseases of the central nervous system (CNS) from animals to humans remains challenging, with...
10.
Thompson C, Fallon J, Mathews M, Charlins P, Remling-Mulder L, Kovarova M, et al.
AIDS
. 2017 Jun;
31(12):1669-1678.
PMID: 28590331
Objectives: Drug transporters affect antiretroviral therapy (ART) tissue disposition, but quantitative measures of drug transporter protein expression across preclinical species are not available. Our objective was to use proteomics to...